{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:31:01Z","timestamp":1786998661357,"version":"build-2736575974"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.vph.2026.107604","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T04:05:52Z","timestamp":1774929952000},"page":"107604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nanocarrier-based drug delivery strategies for Raynaud's phenomenon: Overcoming microvascular and perfusion barriers"],"prefix":"10.1016","volume":"163","author":[{"given":"Sangeetha","family":"Shanmugam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandya","family":"Muthu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2026.107604_bb0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2026.107604_bb0010","series-title":"Genetic Investigation of Primary Raynaud\u2019s Phenomenon and Systemic Sclerosis","author":"Susol","year":"1999"},{"key":"10.1016\/j.vph.2026.107604_bb0015","first-page":"264","article-title":"Raynaud phenomenon in children","volume":"65","author":"Goldman","year":"2019","journal-title":"Can. Fam. Physician"},{"key":"10.1016\/j.vph.2026.107604_bb0020","first-page":"273","article-title":"Raynaud's phenomenon: a vascular acrosyndrome that requires long-term care","volume":"118","author":"Klein-Weigel","year":"2021","journal-title":"Dtsch. Arztebl. Int."},{"key":"10.1016\/j.vph.2026.107604_bb0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMcp013013","article-title":"Clinical practice. Raynaud's phenomenon","volume":"347","author":"Wigley","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.vph.2026.107604_bb0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/2397198319826467","article-title":"Raynaud\u2019s phenomenon","volume":"4","author":"Herrick","year":"2019","journal-title":"J. Scleroderma Relat. Disord."},{"key":"10.1016\/j.vph.2026.107604_bb0035","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2026.107604_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2006.07.002","article-title":"Raynaud's phenomenon","volume":"74","author":"Gayraud","year":"2007","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.vph.2026.107604_bb0045","first-page":"467","article-title":"Cold climate could be an etiologic factor involved in Raynaud's phenomenon physiopathology: epidemiological investigation from 954 consultations in general practice","volume":"34","author":"Plissonneau Duquene","year":"2015","journal-title":"Int. Angiol."},{"key":"10.1016\/j.vph.2026.107604_bb0050","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1002\/art.1780390717","article-title":"Familial aggregation of primary Raynaud's disease","volume":"39","author":"Freedman","year":"1996","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11926-002-0007-z","article-title":"Raynaud's phenomenon: epidemiology and risk factors","volume":"4","author":"Fraenkel","year":"2002","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.vph.2026.107604_bb0060","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0065","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1024\/0301-1526\/a000661","article-title":"ESVM guidelines\u2014the diagnosis and management of Raynaud's phenomenon","volume":"46","author":"Belch","year":"2017","journal-title":"Vasa"},{"key":"10.1016\/j.vph.2026.107604_bb0070","first-page":"879","article-title":"Geographic variation in the prevalence of Raynaud's phenomenon: a 5 region comparison","volume":"24","author":"Maricq","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0075","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bmj.287.6404.1499","article-title":"Role of cold and emotional stress in Raynaud's disease and scleroderma","volume":"287","author":"Freedman","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.vph.2026.107604_bb0080","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fphar.2016.00438","article-title":"Raynaud's phenomenon: a brief review of the underlying mechanisms","volume":"7","author":"Fardoun","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.vph.2026.107604_bb0085","doi-asserted-by":"crossref","first-page":"H1955","DOI":"10.1152\/ajpheart.00306.2007","article-title":"Estrogen increases smooth muscle expression of alpha2C-adrenoceptors and cold-induced constriction of cutaneous arteries","volume":"293","author":"Eid","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2026.107604_bb0090","doi-asserted-by":"crossref","first-page":"208","DOI":"10.7326\/0003-4819-129-3-199808010-00009","article-title":"The association of estrogen replacement therapy and the Raynaud phenomenon in postmenopausal women","volume":"129","author":"Fraenkel","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.vph.2026.107604_bb0095","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/1529-0131(200007)43:7<1641::AID-ANR30>3.0.CO;2-Y","article-title":"A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon","volume":"43","author":"Susol","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0100","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1590\/1806-9282.65.10.1314","article-title":"Raynaud's phenomenon in the occupational context","volume":"65","author":"Cordeiro","year":"2019","journal-title":"Rev. Assoc. Med. Bras. (1992)"},{"key":"10.1016\/j.vph.2026.107604_bb0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10038-006-0038-9","article-title":"Glutathione S-transferase M1 and GST T1 genetic polymorphisms and Raynaud's phenomenon in French vinyl chloride monomer-exposed workers","volume":"51","author":"Fontana","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.vph.2026.107604_bb0110","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.vph.2026.107604_bb0115","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/1529-0131(199902)42:2<306::AID-ANR13>3.0.CO;2-G","article-title":"Different factors influencing the expression of Raynaud's phenomenon in men and women","volume":"42","author":"Fraenkel","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/ije\/20.1.221","article-title":"Demographic, social and clinical correlates of Raynaud phenomenon","volume":"20","author":"Keil","year":"1991","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.vph.2026.107604_bb0125","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","article-title":"Mechanisms of Raynaud's disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vasc. Med."},{"key":"10.1016\/j.vph.2026.107604_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1024\/0301-1526.37.S73.3","article-title":"Clinical characteristics of primary, secondary and suspected secondary Raynaud\u2019s syndrome and diagnostic transition in the long-term follow-up: a retrospective study in 900 patients","volume":"37","author":"Heidrich","year":"2008","journal-title":"Vasa"},{"key":"10.1016\/j.vph.2026.107604_bb0135","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","article-title":"Raynaud's phenomenon\u2014an update on diagnosis, classification and management","volume":"38","author":"Pauling","year":"2019","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0140","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vph.2026.107604_bb0145","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","article-title":"Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation","volume":"94","author":"Bailey","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.vph.2026.107604_bb0150","doi-asserted-by":"crossref","first-page":"H243","DOI":"10.1152\/ajpheart.01305.2004","article-title":"Reactive oxygen species from smooth muscle mitochondria initiate cold-induced constriction of cutaneous arteries","volume":"289","author":"Bailey","year":"2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2026.107604_bb0155","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2026.107604_bb0160","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0165","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0889-857X(05)70300-8","article-title":"Raynaud's phenomenon","volume":"22","author":"Wigley","year":"1996","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.vph.2026.107604_bb0170","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2133.1992.tb00100.x","article-title":"Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy","volume":"126","author":"Freemont","year":"1992","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.vph.2026.107604_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.651","article-title":"Endothelial dysfunction: molecular mechanisms and clinical implications","volume":"5","author":"Wang","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.vph.2026.107604_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122570","article-title":"Nanocarriers based novel and effective drug delivery system","volume":"632","author":"Khizar","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.vph.2026.107604_bb0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0895-7061(95)00030-S","article-title":"Endothelial cell signaling and endothelial dysfunction","volume":"8","author":"Flavahan","year":"1995","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.vph.2026.107604_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynaud's phenomenon: pathogenesis and management","volume":"59","author":"Bakst","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.vph.2026.107604_bb0195","doi-asserted-by":"crossref","first-page":"580","DOI":"10.7861\/clinmed.2020-0754","article-title":"Raynaud's phenomenon","volume":"20","author":"Haque","year":"2020","journal-title":"Clin. Med."},{"key":"10.1016\/j.vph.2026.107604_bb0200","first-page":"314","article-title":"Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis","volume":"25","author":"Yamamoto","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0205","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/0140-6736(90)92766-B","article-title":"Serum endothelin-1 concentrations and cold provocation in primary Raynaud\u2019s phenomenon","volume":"336","author":"Zamora","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2026.107604_bb0210","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/art.11060","article-title":"Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease","volume":"48","author":"Rajagopalan","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0215","first-page":"1268","article-title":"Localization of endothelin-1 and its binding sites in scleroderma skin","volume":"21","author":"Vancheeswaran","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0220","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.11364","article-title":"Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors","volume":"50","author":"Kawaguchi","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0225","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.it.2006.10.004","article-title":"Angiopoietins: a link between angiogenesis and inflammation","volume":"27","author":"Fiedler","year":"2006","journal-title":"Trends Immunol."},{"key":"10.1016\/j.vph.2026.107604_bb0230","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1093\/rheumatology\/keq392","article-title":"Angiopoietins-1 and -2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease","volume":"50","author":"Michalska-Jakubus","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vph.2026.107604_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1042\/cs0950249","article-title":"Lack of habituation of the pattern of cardiovascular response evoked by sound in subjects with primary Raynaud's disease","volume":"95","author":"Edwards","year":"1998","journal-title":"Clin. Sci."},{"key":"10.1016\/j.vph.2026.107604_bb0240","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/cs0960577","article-title":"Cardiovascular responses evoked by mild cool stimuli in primary Raynaud's disease: the role of endothelin","volume":"96","author":"Edwards","year":"1999","journal-title":"Clin. Sci."},{"key":"10.1016\/j.vph.2026.107604_bb0245","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","article-title":"Calcitonin gene-related peptide: physiology and pathophysiology","volume":"94","author":"Russell","year":"2014","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.vph.2026.107604_bb0250","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.rdc.2004.10.005","article-title":"Estrogens and neuropeptides in Raynaud's phenomenon","volume":"31","author":"Generini","year":"2005","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.vph.2026.107604_bb0255","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-5347(25)00268-X","article-title":"Human postjunctional alpha-1 and alpha-2 adrenoceptors: differential distribution in arteries of the limbs","volume":"241","author":"Flavahan","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.vph.2026.107604_bb0260","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0889-857X(03)00021-8","article-title":"The vasculopathy of Raynaud's phenomenon and scleroderma","volume":"29","author":"Flavahan","year":"2003","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.vph.2026.107604_bb0265","doi-asserted-by":"crossref","first-page":"H1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","article-title":"Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries","volume":"278","author":"Chotani","year":"2000","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.vph.2026.107604_bb0270","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/mol.60.6.1195","article-title":"Cooling evokes redistribution of alpha2C-adrenoceptors from Golgi to plasma membrane in transfected human embryonic kidney 293 cells","volume":"60","author":"Jeyaraj","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.vph.2026.107604_bb0275","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/art.20214","article-title":"Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease","volume":"50","author":"Furspan","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0280","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/rheumatology\/keh517","article-title":"Cooling-induced contraction and protein tyrosine kinase activity of isolated arterioles in secondary Raynaud's phenomenon","volume":"44","author":"Furspan","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vph.2026.107604_bb0285","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/030097401753180372","article-title":"Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon and Raynaud's phenomenon secondary to systemic sclerosis","volume":"30","author":"Silveri","year":"2001","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0290","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/jcp.37.2.182","article-title":"Assessment of platelet function in patients with Raynaud's syndrome","volume":"37","author":"Hutton","year":"1984","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.vph.2026.107604_bb0295","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1136\/bmj.292.6527.1037","article-title":"Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon","volume":"292","author":"Reilly","year":"1986","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"key":"10.1016\/j.vph.2026.107604_bb0300","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/rheumatology\/41.8.869","article-title":"Elevated expression of the genes encoding TNF-alpha and thromboxane synthase in leucocytes from patients with systemic sclerosis","volume":"41","author":"Young","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vph.2026.107604_bb0305","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/cs0860269","article-title":"Plasma levels of 5-hydroxytryptamine during sympathetic stimulation and in Raynaud's phenomenon","volume":"86","author":"Coffman","year":"1994","journal-title":"Clin. Sci."},{"key":"10.1016\/j.vph.2026.107604_bb0310","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1093\/rheumatology\/36.10.1045","article-title":"The coagulation\/fibrinolysis balance in systemic sclerosis: evidence for a haematological stress syndrome","volume":"36","author":"Ames","year":"1997","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0315","first-page":"1477","article-title":"Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis","volume":"21","author":"Herrick","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0320","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S0140-6736(76)92651-9","article-title":"Abnormal blood viscosity in Raynaud's phenomenon","volume":"1","author":"Goyle","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.vph.2026.107604_bb0325","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mvn.2001.117786","article-title":"Raynaud's phenomenon","volume":"19","author":"O'Connor","year":"2001","journal-title":"J. Vasc. Nurs."},{"key":"10.1016\/j.vph.2026.107604_bb0330","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5152\/eurjrheum.2020.19124","article-title":"New perspectives in the imaging of Raynaud's phenomenon","volume":"7","author":"Herrick","year":"2020","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0335","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1148\/radiographics.22.3.g02ma16583","article-title":"Contrast-enhanced MR angiography of the hand","volume":"22","author":"Connell","year":"2002","journal-title":"Radiographics"},{"key":"10.1016\/j.vph.2026.107604_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102458","article-title":"Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis","volume":"19","author":"Smith","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.vph.2026.107604_bb0345","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.clineuro.2013.09.027","article-title":"Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis","volume":"115","author":"Rot","year":"2013","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.vph.2026.107604_bb0350","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/sarh.2002.34606","article-title":"Interferon-induced Raynaud's syndrome","volume":"32","author":"Schapira","year":"2002","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.vph.2026.107604_bb0355","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.autrev.2017.11.036","article-title":"The role of capillaroscopy and thermography in the assessment and management of Raynaud's phenomenon","volume":"17","author":"Herrick","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.vph.2026.107604_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102394","article-title":"Fast track algorithm: how to differentiate a \u201cscleroderma pattern\u201d from a \u201cnon-scleroderma pattern\u201d","volume":"18","author":"Smith","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.vph.2026.107604_bb0365","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/BF01071951","article-title":"Esophageal dysfunction and Raynaud's phenomenon in patients with scleroderma","volume":"21","author":"Hurwitz","year":"1976","journal-title":"Am J Dig Dis"},{"key":"10.1016\/j.vph.2026.107604_bb0370","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/rheumatology\/35.8.752","article-title":"Raynaud's phenomenon in rheumatoid arthritis","volume":"35","author":"Saraux","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0375","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-011-1727-0","article-title":"The association of Raynaud's syndrome with rheumatoid arthritis\u2014a meta-analysis","volume":"30","author":"Hartmann","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0380","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.vph.2026.107604_bb0385","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2015.2","article-title":"Systemic sclerosis","volume":"1","author":"Allanore","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.vph.2026.107604_bb0390","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1177\/1759720X17740074","article-title":"Evidence-based management of Raynaud's phenomenon","volume":"9","author":"Herrick","year":"2017","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"10.1016\/j.vph.2026.107604_bb0395","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud's phenomenon","volume":"48","author":"Maverakis","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.vph.2026.107604_bb0400","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41584-021-00685-0","article-title":"Detection of microvascular changes in systemic sclerosis and other rheumatic diseases","volume":"17","author":"Cutolo","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.vph.2026.107604_bb0405","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.rdc.2007.12.002","article-title":"The heart in scleroderma","volume":"34","author":"Champion","year":"2008","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.vph.2026.107604_bb0410","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00296-012-2449-6","article-title":"Is there a difference in systemic lupus erythematosus with and without Raynaud\u2019s phenomenon?","volume":"33","author":"Pavlov-Dolijanovic","year":"2013","journal-title":"Rheumatol. Int."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189126000248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:33:04Z","timestamp":1786995184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189126000248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":82,"alternative-id":["S1537189126000248"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2026.107604","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanocarrier-based drug delivery strategies for Raynaud's phenomenon: Overcoming microvascular and perfusion barriers","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2026.107604","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107604"}}